Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Montana Wildhack who wrote (9799)	6/14/2002 3:03:44 PM
From: arizzzona	Read Replies (2) of 14101

Bravo, Dimethaid. I think this a great move. Essentially, by staying with Provalis, we were writing off the entire U.K. market. Now we have a second crack at it. I think Provalis didn't see this coming and personally, I'm glad DMX didn't get strung along with a lot of happy words and promises. It's about results. To me, that's business. "In exchange for the rights, Provalis was expected to meet minimum sales targets by March. Dimethaid was entitle to terminate the contract if those targets were not achieved." ....... "Provalis Healthcare believes that it is not in breach of its obligations under the Agreement, that Dimethaid is not entitled to terminate the Agreement and that Provalis Healthcare remains entitled to distribute Pennsaid in the United Kingdom. Provalis is currently seeking advice from its advisers, and will be contacting Dimethaid to seek to resolve the issue. Provalis will update the market further in due course." Face saving effort, IMO. I added a bit more today. Looks like another case of DMX Creep. DMX Creep: A unique condition that afflicts portfolios containing Dimethaid. No known cure. : )

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next